두개내 동맥류 시장 : 치료법별, 동맥류 유형별, 환자 연령층별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Intracranial Aneurysm Market is projected to grow by USD 8.38 billion at a CAGR of 22.95% by 2032.

Introduction

The intracranial aneurysm market spans diagnosis, surveillance, and treatment of weakened cerebral blood vessels that may remain asymptomatic or rupture into aneurysmal subarachnoid hemorrhage. Peer-reviewed epidemiology commonly estimates unruptured intracranial aneurysms in about 3% of adults, while rupture is less common but clinically severe, making early detection, rupture-risk assessment, and timely intervention central to patient outcomes.

Growth is supported by wider access to CT angiography, MR angiography, digital subtraction angiography, and advanced endovascular devices such as detachable coils, stents, flow diverters, intrasaccular implants, and adjunctive microcatheters. Demand is shaped by aging populations, hypertension and smoking prevalence, improved neurovascular referral networks, and the global shift toward minimally invasive neurointervention for complex brain aneurysm treatment.

Transformative Shifts in the Intracranial Aneurysm Landscape

The intracranial aneurysm landscape is moving from open microsurgical clipping as the default approach toward patient-specific decision-making that combines endovascular therapy, surgical expertise, and imaging-based surveillance. Coiling remains important for many saccular aneurysms, while flow diversion and intrasaccular devices are expanding options for wide-neck, bifurcation, complex, and previously difficult-to-treat lesions.

Procurement is also shifting from product-based purchasing to evidence-led platform selection. Hospitals increasingly evaluate device deliverability, occlusion durability, retreatment rates, antiplatelet requirements, training needs, and compatibility with biplane angiography suites. Regulatory expectations, real-world registries, and multidisciplinary neurovascular boards are becoming decisive factors in adoption.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across the intracranial aneurysm pathway rather than a single-point technology. In imaging, machine-learning tools are being studied to support aneurysm detection on CTA and MRA, vessel segmentation, 3D morphology measurement, and prioritization of suspected findings for radiology and neurosurgery review.

AI also supports rupture-risk modeling by combining size, location, morphology, hemodynamic markers, patient history, and longitudinal imaging changes. Its commercial value will depend on prospective validation, explainability, integration with PACS and electronic health records, cybersecurity safeguards, and clinician oversight to avoid false reassurance or unnecessary intervention.

Key Regional Insights

North America benefits from mature stroke systems, high MRI and CT utilization, FDA-cleared neurovascular technologies, and reimbursement structures that support complex endovascular procedures. The United States is the region's primary innovation and procedure hub, while Canada's regionalized referral networks support standardized intracranial aneurysm care. Europe maintains strong clinical research capacity across major neurosurgical centers, but EU Medical Device Regulation has increased evidence and compliance requirements, lengthening commercialization timelines while improving post-market rigor.

Asia-Pacific is the highest-volume opportunity, supported by Japan's advanced neurointerventional base, China's hospital expansion, India's private tertiary-care growth, and sophisticated centers in Australia and South Korea. Latin America is led by Brazil and Mexico, though access varies by payer, specialist availability, and urban concentration. The Middle East is expanding through GCC hospital investment, tertiary neuroscience programs, and medical tourism strategies, while Africa remains constrained by neurosurgical workforce density, angiography access, imaging availability, and affordability.

Key Group Insights

G7 markets anchor premium device adoption, clinical trials, and guideline-driven aneurysm care, supported by high imaging density, established neurovascular centers, and robust post-market surveillance expectations. The European Union adds regulatory harmonization and multicenter research depth, although evidence-generation demands under MDR are reshaping market-entry strategies and increasing the importance of clinical documentation, safety monitoring, and traceability.

BRICS countries represent scale, rising neurointerventional procedure volumes, and increasing domestic manufacturing interest, especially in China and India, where hospital capacity and specialist training are expanding. ASEAN is heterogeneous, with Singapore and Thailand offering advanced neurointervention while other members prioritize capacity building, referral pathways, and affordability. GCC systems are investing in tertiary neuroscience hubs, advanced imaging, and medical tourism. NATO economies overlap with many high-income procurement systems where supply resilience, cybersecurity, device traceability, and uninterrupted access to critical neurovascular technologies are strategic priorities.

Key Country Insights

The United States remains central to innovation, FDA submissions, real-world evidence, and premium endovascular adoption, while Canada emphasizes publicly funded access, provincial procurement, and regionalized neurovascular referral. Mexico and Brazil are the primary Latin American growth centers, combining private-sector demand with public access challenges and uneven availability of advanced angiography suites.

In Europe, the United Kingdom, Germany, France, Italy, and Spain sustain strong aneurysm treatment networks through established neurosurgery, neuroradiology, and stroke-care infrastructure, though reimbursement and procurement differ by country. Russia has capable tertiary centers but uneven regional access. China is scaling neurointervention rapidly through large hospital networks and specialist training, India is expanding through private hospitals and government insurance initiatives, Japan has deep procedural expertise and aging-population demand, Australia offers high-quality referral networks, and South Korea combines advanced imaging, skilled operators, and technology-forward hospitals.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinical evidence that links device selection to durable occlusion, lower retreatment, safety, functional recovery, and quality-of-life outcomes. Registries, health-economic studies, and physician-led education are essential in an intracranial aneurysm market where aneurysm morphology, rupture status, comorbidities, and operator experience strongly influence treatment decisions.

Manufacturers and service providers should build AI-ready imaging workflows, support interoperability with hospital systems, and offer structured training for complex flow-diversion, stent-assisted coiling, and intrasaccular techniques. Region-specific pricing, local distributor quality controls, regulatory readiness, and post-market surveillance will be critical for expanding access without compromising safety.

Research Methodology

This executive summary is based on triangulation of peer-reviewed neurovascular literature, public regulatory sources, health-system indicators, clinical guideline references, and macroeconomic data from recognized institutions. Findings are validated through consistency checks across epidemiology, procedure trends, device adoption patterns, imaging infrastructure, reimbursement dynamics, and regional healthcare capacity.

The methodology emphasizes data-backed interpretation rather than speculative market claims. Segmentation considers diagnostics, endovascular devices, surgical solutions, treatment settings, and geography. Qualitative assessment is integrated with evidence on disease prevalence, hospital capability, regulatory pathways, reimbursement dynamics, specialist availability, and technology readiness.

Conclusion

Intracranial aneurysm care is entering a more precise, evidence-driven phase defined by advanced imaging, minimally invasive neurointervention, AI-enabled decision support, and stronger post-market accountability. The strongest opportunities are expected where specialized operators, modern angiography infrastructure, reimbursement support, and validated technologies converge.

For industry participants, success will depend on proving clinical value, supporting multidisciplinary care, and adapting commercialization models to regional healthcare realities. Organizations that combine safe innovation, robust evidence, training, and scalable digital integration will be best positioned in the global intracranial aneurysm market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Intracranial Aneurysm Market, by Treatment Type

• 7.1. Endovascular Coiling
• 7.2. Flow Diversion
• 7.3. Surgical Clipping

8. Intracranial Aneurysm Market, by Aneurysm Type

• 8.1. Saccular Aneurysm
• 8.2. Fusiform Aneurysm
• 8.3. Mycotic Aneurysm

9. Intracranial Aneurysm Market, by Patient Age Group

• 9.1. Adult
• 9.2. Geriatric
• 9.3. Pediatric

10. Intracranial Aneurysm Market, by End Users

• 10.1. Ambulatory Surgery Centers
• 10.2. Diagnostic Centers
• 10.3. Hospitals

11. Intracranial Aneurysm Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Intracranial Aneurysm Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Intracranial Aneurysm Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Acandis GmbH
• 15.2. ASAHI INTECC CO., LTD.
• 15.3. B. Braun Melsungen AG
• 15.4. Balt Group
• 15.5. Cerus Endovascular Ltd.
• 15.6. Evasc Neurovascular Enterprises ULC
• 15.7. InspireMD, Inc.
• 15.8. Integra LifeSciences
• 15.9. Johnson & Johnson
• 15.10. Kaneka Medix Corporation
• 15.11. Medtronic plc
• 15.12. MicroPort Scientific Corporation
• 15.13. Penumbra, Inc.
• 15.14. phenox GmbH
• 15.15. Rapid Medical
• 15.16. Stryker Corporation
• 15.17. Terumo Corporation
• 15.18. Wallaby Medical